CN102120017B - Chinese medicinal preparation for treating uterus myoma - Google Patents
Chinese medicinal preparation for treating uterus myoma Download PDFInfo
- Publication number
- CN102120017B CN102120017B CN2011100444070A CN201110044407A CN102120017B CN 102120017 B CN102120017 B CN 102120017B CN 2011100444070 A CN2011100444070 A CN 2011100444070A CN 201110044407 A CN201110044407 A CN 201110044407A CN 102120017 B CN102120017 B CN 102120017B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicinal
- hysteromyoma
- chinese
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention belongs to a human Chinese medicinal preparation for treating uterus myoma. The preparation is prepared from the following Chinese medicinal raw materials in parts by weight: 9 to 15 parts of common burreed rhizome, 9 to 15 parts of zedoary, 8 to 14 parts of peach kernel, 8 to 14 parts of cassia twig, 16 to 24 parts of tuckahoe, 9 to 15 parts of root bark of peony, 10 to 18 parts of red peony root, and 8 to 14 parts of Szechuan lovage rhizome. The main Chinese medicinal preparation for activating blood, promoting qi circulation, softening hardness to dissipate stagnation and treating the uterus myoma shows that the uterus myoma is controlled in different degrees; the tumor body is reduced; the symptoms such as irregular menstruation, waist and abdomen pain, intimitis, ovarian cysts and the like are obviously improved; and the total effective rate is 95.3 percent.
Description
Technical field
The invention belongs to personnel's human drugs technical field, particularly a kind of Chinese medicine preparation of treating hysteromyoma.
Background technology
Hysteromyoma (Hysteromyoma) claim leiomyoma of uterus again, is the modal a kind of benign tumors of female sex organs.How asymptomatic, minority shows as vaginal hemorrhage, and abdominal part touches swollen thing and pressure symptom etc.As when taking place, torsion of pedicle or other situation can cause pain.Common with multiple myomata.The definite etiology unknown of primary disease, modern western medicine is taked gonadal hormone or operative treatment, does not still have other desirable therapies.
In addition, Chinese medicine has extraordinary therapeutic effect to hysteromyoma, need not to hysterectomize, and also need not high expense.The formation of hysteromyoma has endogenous cause of ill and exopathogenic factor.Outer because the six evils attacks uterus in an opponent's defence, or the exhaustion due to sexual indulgence fecund; In because damaged by excess of seven emotions, visceral dysfunction, the impairment of chong and ren channels, qi depression to blood stasis is due to the blood agglomeration uterus.Be rule of treatment with " dispersing tumor is not forgotten in hemostasis, and dispersing tumor is taken into account hemostasis ", control and work as, the dissipation lump in the abdomen with strengthening vital QI to eliminate pathogenic factors.The Chinese traditional treatment method comprises:
1, Drug therapy: Chinese medicine is having unique mode in treatment aspect the hysteromyoma, and wherein alizarin root of Dahurian angelica palace tumor is just pasted with the form appearance of black plaster, and black plaster has been brought into play important function in the Chinese traditional treatment field; Be one of soul of Chinese traditional treatment, ancestor's Wu Shangxian of transmission from master to disciple inner disease outer treat is theoretical, utilizes interior disease external therapy; Drug effect infiltration lesion locations is not injuring under the kidney situation, thereby reaches the purpose of treatment; This method is successfully cured a lot of female friends at present, and obtains a large amount of favorable comments.
2, the method for acupuncture: acupuncture is divided into the skill of handling needles and moxibustion therapy, and the skill of handling needles is to thrust acupuncture needle in patient's body by certain acupuncture point, use twisted with put forward the manipulation of acupuncture such as slotting and treat disease.Moxibustion therapy is to smoke the skin that burns to the Folium Artemisiae Argyi that is burning by certain acupuncture point, utilizes the stimulation of heat to treat disease.Acupuncture and moxibustion therapy mainly is that effect is exactly dredging the meridian, YIN and YANG balance regulating, strengthening vital QI to eliminate pathogenic factors.Aspect the treatment hysteromyoma significant curative effect is being arranged also, but this method must be through the dialectical treatment of professional acupuncture practitioner, so can not get generally promoting.
This shows; The traditional Chinese medical science can thoroughly be cured, and the advantage of the traditional Chinese medical science just is to exempt misery that operation brings and Western medicine hormone to the harm of health, takes stopgap measures and effects a permanent cure; Tackle the problem at its root, key issue is to adopt Chinese traditional treatment to select medicine effective, short treating period.
Summary of the invention
The object of the invention provides a kind of Chinese medicine preparation of treating hysteromyoma.
The traditional Chinese medical science thinks that hysteromyoma forms because of visceral dysfunction, qi depression to blood stasis.So how the Chinese traditional treatment hysteromyoma is main with blood circulation promoting and blood stasis dispelling, repercussive eliminating stagnation, heat-clearing and toxic substances removing, depressed liver-energy dispersing and QI regulating, blood-activating analgetic.The Chinese traditional treatment hysteromyoma can improve outgrowth endometrial blood circulation; The simple property hypertrophy of flesh layer is faded away; Outgrowth connective tissue deliquescing, thus play the therapeutical effect that regulating menstruation, hemostasis, pain disappear, recover ovarian function, can control hysteromyoma tumor bulk-growth effectively; Make the tumor body softening gradually, dissipate at last.
The present invention treats the Chinese medicine preparation of hysteromyoma, and it is to process with following parts by weight of Chinese traditional medicine raw material: triangular 9-15, Rhizoma Curcumae 9-15, Semen Persicae 8-14, Ramulus Cinnamomi 8-14, Poria 16-24, Cortex Moutan 9-15, Radix Paeoniae Rubra 10-18, Rhizoma Chuanxiong 8-14.
Further, the present invention treats the Chinese medicine preparation of hysteromyoma, and it is to process with following parts by weight of Chinese traditional medicine raw material: triangular 10-12, Rhizoma Curcumae 10-12, Semen Persicae 9-12, Ramulus Cinnamomi 9-12, Poria 19-21, Cortex Moutan 9-15, Radix Paeoniae Rubra 14-16, Rhizoma Chuanxiong 9-12.
A nearlyer step, the present invention treats the Chinese medicine preparation of hysteromyoma, and it is to process with following parts by weight of Chinese traditional medicine raw material: triangular 12, Rhizoma Curcumae 12, Semen Persicae 10, Ramulus Cinnamomi 10, Poria 20, Cortex Moutan 13, Radix Paeoniae Rubra 15, Rhizoma Chuanxiong 10.
It is main Chinese medicine preparation treatment hysteromyoma that the present invention adopts with blood-activating and qi-promoting, hard masses softening and resolving; Hysteromyoma obtains control in various degree after the proof medication; The tumor body dwindles; Menoxenia, waist abdomen pain and intimitis and with symptoms such as ovarian cyst be improved significantly, total effective rate is 95.3%.
The specific embodiment
Embodiment 1: take by weighing raw material of Chinese medicine (in gram), triangular 12, Rhizoma Curcumae 12, Semen Persicae 10, Ramulus Cinnamomi 10, Poria 20, Cortex Moutan 13, Radix Paeoniae Rubra 15, Rhizoma Chuanxiong 10, Cortex Moutan adopt Chinese liquor to concoct the back to merge with other raw materials, process water decoction.
Embodiment 2: take by weighing raw material of Chinese medicine (in gram), triangular 9, Rhizoma Curcumae 15, Semen Persicae 8, Ramulus Cinnamomi 14, Poria 16, Cortex Moutan 15, Radix Paeoniae Rubra 10, Rhizoma Chuanxiong 14, Cortex Moutan adopt Chinese liquor to concoct the back to merge with other raw materials, process capsule.
Embodiment 3: take by weighing raw material of Chinese medicine (in gram), triangular 15, Rhizoma Curcumae 9, Semen Persicae 14, Ramulus Cinnamomi 8, Poria 24, Cortex Moutan 9, Radix Paeoniae Rubra 18, Rhizoma Chuanxiong 8, Cortex Moutan adopt Chinese liquor to concoct the back to merge with other raw materials, process the watered pill.
The present invention treats hysteromyoma 169 routine clinical reports
The inventor has adopted since year in June, 2008 with blood-activating and qi-promoting, hard masses softening and resolving and is main Chinese medicine preparation treatment hysteromyoma 169 examples and carries out clinical data and collect; Hysteromyoma obtains control in various degree after the medication; The tumor body dwindles, menoxenia, waist abdomen pain and intimitis and with symptoms such as ovarian cyst be improved significantly, total effective rate is 95.3%; Proof the present invention has satisfied clinical efficacy to the treatment hysteromyoma, and existing report as follows.
1, clinical data
1.1 case is selected
In June, 2008～2010 belong to outpatient service by the inventor and accept patients with uterine myoma 169 examples for medical treatment year October, and the age is 30～49 years old, and the course of disease is more than 1 year, and Chinese medical discrimination belongs to the blood stasis asthenia of qi and blood person that holds concurrently.
1.2 diagnostic criteria
" traditional Chinese medical science disease diagnosis criterion of therapeutical effect " formulated with State Administration of Traditional Chinese Medicine as the clinical diagnosis foundation, and has B ultrasonic to confirm.
2, treatment and observational technique
Adopt preparation of the present invention, consumption is decided according to patient's disease and body constitution, with the disease plus-minus, is controlled at each 6-9 gram, every day three times.Take January continuously, did 1 ultrasound diagnosis (menstruation is done in clean 4～7 days) in every month, observe muscular tumor and change situation.
3, criterion of therapeutical effect
In " traditional Chinese medical science Clinical Researches of New Drugs guideline " according to the Ministry of Public Health formulation uterine fibroid disease efficacy assessment standard is arranged, recovery from illness: MBV is reduced to normally, and hysteromyoma disappears; The uterus obviously dwindles, produce effects: MBV reduces, and hysteromyoma dwindles; The uterus dwindles; Invalid: MBV does not subtract, and the hysteromyoma size does not have change, uterus size no change.
4, therapeutic outcome
Treat altogether in 169 examples, clinical recovery 135 examples account for 80%; Produce effects 26 examples account for 15.4%, and invalid 8 examples account for 4.7%, and total effective rate accounts for 95.3%.Simultaneously, patient's menoxenia, waist abdomen pain be improved significantly, also well improved with the patient's of intimitis and ovarian cyst symptom in addition, prove that preparation of the present invention also produces effect to these gynaecopathia.
5, sum up
Hysteromyoma belongs to traditional Chinese medical science abdominal mass category, and " the no stasis of blood does not become ", " disharmony between QI and blood, blood stasis stagnates, and becomes with the stasis of blood " is so " hard masses should be resolved gradually, diseases with invaded pathogens should be treated by expelling, disease caused by accumulations of pathogen should be treated with therapy of dispersion, disease with retention of pathogen in the body should be treated by elimination therapy ".Primary disease is many owing to depressed rage impairing the liver, stagnation of QI due to depression of the liver, and worry impairing spleen, dysfunction of the spleen in transportation accumulates in the phlegm-damp, so that liver spleen stagnation of Qi and phelgm, and the stasis of blood forms long-pending piece.Modern medicine study shows, hysteromyoma, chronic pelvic inflammatory enclosed mass, the generation of the irregular anovulatory dysfunctional uterine hemorrhage that takes off of endometrium all with the body endocrine disturbance, immunologic function goes down, metabolism disorder is relevant.So use blood circulation promoting and blood stasis dispelling, hysteromyoma is treated in hard masses softening and resolving ruling by law has good effect.Modern pharmacological research thinks that drug for invigorating blood circulation and eliminating stasis can promote fibrosis organization softening and absorption, and the prevention proliferation of fibrous tissue is degenerated and disappeared to eliminate enclosed mass, and this is one of the advantage of Chinese medicine hysteromyoma just, can reach excellent curative.
Claims (4)
1. the Chinese medicine preparation of treatment hysteromyoma is characterized in that processing with following parts by weight of Chinese traditional medicine raw material: triangular 9-15, Rhizoma Curcumae 9-15, Semen Persicae 8-14, Ramulus Cinnamomi 8-14, Poria 16-24, Cortex Moutan 9-15, Radix Paeoniae Rubra 10-18, Rhizoma Chuanxiong 8-14.
2. the Chinese medicine preparation of treatment hysteromyoma according to claim 1 is characterized in that processing with following parts by weight of Chinese traditional medicine raw material: triangular 10-12, Rhizoma Curcumae 10-12, Semen Persicae 9-12, Ramulus Cinnamomi 9-12, Poria 19-21, Cortex Moutan 9-15, Radix Paeoniae Rubra 14-16, Rhizoma Chuanxiong 9-12.
3. the Chinese medicine preparation of treatment hysteromyoma according to claim 2 is characterized in that processing with following parts by weight of Chinese traditional medicine raw material: triangular 12, Rhizoma Curcumae 12, Semen Persicae 10, Ramulus Cinnamomi 10, Poria 20, Cortex Moutan 13, Radix Paeoniae Rubra 15, Rhizoma Chuanxiong 10.
4. according to the Chinese medicine preparation of claim 1 or 2 or 3 described treatment hysteromyoma, it is characterized in that Cortex Moutan adopts Chinese liquor to concoct.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100444070A CN102120017B (en) | 2011-02-24 | 2011-02-24 | Chinese medicinal preparation for treating uterus myoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100444070A CN102120017B (en) | 2011-02-24 | 2011-02-24 | Chinese medicinal preparation for treating uterus myoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102120017A CN102120017A (en) | 2011-07-13 |
| CN102120017B true CN102120017B (en) | 2012-07-18 |
Family
ID=44248745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100444070A Expired - Fee Related CN102120017B (en) | 2011-02-24 | 2011-02-24 | Chinese medicinal preparation for treating uterus myoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102120017B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102847060A (en) * | 2012-08-15 | 2013-01-02 | 枣庄汇康医疗用品有限公司 | Traditional Chinese medicine composition for treating uterine myoma and preparation method thereof |
| CN103690896A (en) * | 2013-12-18 | 2014-04-02 | 太仓市伟基生物科技有限公司 | Traditional Chinese medicine fumigating formula for treating uterine fibroid |
| CN103893692A (en) * | 2014-03-05 | 2014-07-02 | 魏茂芳 | Pharmaceutical composition for treating myoma of uterus |
| CN104784643A (en) * | 2015-04-29 | 2015-07-22 | 赵汝君 | Medicine for treating hysteromyoma, ovarian cyst and endometriosis |
| CN105477560A (en) * | 2016-01-05 | 2016-04-13 | 丁勇剑 | Traditional Chinese medicine preparation for treating fibroid and preparation method and application thereof |
| CN105920282A (en) * | 2016-07-14 | 2016-09-07 | 赵红星 | Traditional Chinese medicine for treating abdominal pains after hysteromyomectomy |
| CN109010688A (en) * | 2018-09-07 | 2018-12-18 | 杭州宽松生物科技有限公司 | A kind of plant extracts and preparation method thereof for treating fibroid |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1125613A (en) * | 1995-09-12 | 1996-07-03 | 王桂兰 | Prescription for treatment of hysteromyoma |
| CN101647984A (en) * | 2009-09-18 | 2010-02-17 | 秦中文 | Traditional Chinese medicine for promoting blood circulation and removing blood stasis |
-
2011
- 2011-02-24 CN CN2011100444070A patent/CN102120017B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1125613A (en) * | 1995-09-12 | 1996-07-03 | 王桂兰 | Prescription for treatment of hysteromyoma |
| CN101647984A (en) * | 2009-09-18 | 2010-02-17 | 秦中文 | Traditional Chinese medicine for promoting blood circulation and removing blood stasis |
Non-Patent Citations (3)
| Title |
|---|
| 徐文婷等.子宫肌瘤中医药研究概况.《辽宁中医药大学学报》.2010,第12卷(第10期),第205-207页. * |
| 李虹等.子宫肌瘤的中医药治疗进展.《临床合理用药》.2010,第3卷(第19期),第152-154页. * |
| 马春芬等.加味桂枝茯苓丸妇科应用举隅.《河南中医》.2006,第26卷(第12期),第11-12页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102120017A (en) | 2011-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102120017B (en) | Chinese medicinal preparation for treating uterus myoma | |
| CN104523865B (en) | Medicine for treating breast diseases | |
| CN102908603A (en) | Chinese medicament for treating hyperplasia of mammary glands | |
| CN1895490A (en) | Production of Chinese medicine and its medicinal pillow for treating cervical spondylosis | |
| CN102309651B (en) | New use of compound traditional Chinese medicine | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN103211886A (en) | Medicament for treating rheumatic arthritis | |
| CN103356932B (en) | A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia | |
| CN102988887A (en) | Chinese medicament for treating ovarian cyst | |
| CN102430096B (en) | Medicament for treating rheumatic or rheumatoid diseases | |
| CN105770294A (en) | Traditional Chinese medicine composition for treating hysteromyoma | |
| CN101698058B (en) | Medicine for treating chronic arthralgia and preparation method thereof | |
| CN103977216A (en) | Traditional Chinese medicinal preparation for treating irradiated brain stem type myeloen cephalospinal disease | |
| CN103349767B (en) | Inula nervosa Wall oil capsule preparation and preparation method thereof | |
| CN103285108B (en) | Chinese medicinal composition treating lumbago | |
| CN100371006C (en) | Chinese traditional medicine formula for curing cysticercosis | |
| CN103372065B (en) | External traditional Chinese medicine for treating arthritis and preparation method thereof | |
| CN102688456B (en) | Chinese medicinal composition for treating chronic prostatitis | |
| CN102205067A (en) | Traditional Chinese medicine composition for treating chronic urticaria | |
| CN105456956A (en) | Traditional Chinese medicine for treating myoma of uterus | |
| CN101983676A (en) | Medicament for treating gynecological blood stasis and qi stagnation | |
| CN105833059A (en) | Chinese medicinal composition for treating psoriasis | |
| CN105770478A (en) | Traditional Chinese medicine composition for treating bladder cancer | |
| CN105749166A (en) | Traditional Chinese medicine composition for treating uterine fibroid | |
| CN105560994A (en) | Traditional Chinese medicine composition for treating prolapse of uterus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHANG CUIXIANG Free format text: FORMER OWNER: ZHANG LAN Effective date: 20120516 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Cuixiang Inventor after: Zhang Lan Inventor after: Qin Haitao Inventor after: Tian Junzheng Inventor before: Zhang Lan Inventor before: Zhang Cuixiang Inventor before: Qin Haitao Inventor before: Tian Junzheng |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG LAN ZHANG CUIXIANG QIN HAITAO TIAN JUNZHENG TO: ZHANG CUIXIANG ZHANGLAN QIN HAITAO TIAN JUNZHENG |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20120516 Address after: The three hospital of Baoji City, Shaanxi Province, 721004 Dongfeng Road, Jintai District No. 45 PLA Applicant after: Zhang Cuixiang Address before: The three hospital of Baoji City, Shaanxi Province, 721004 Dongfeng Road, Jintai District No. 45 PLA Applicant before: Zhang Lan |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120718 Termination date: 20130224 |